Table 1.
Preoperative and postoperative clinicopathological characteristics of the study population (N = 5,339).
| Characteristic | n (%) |
|---|---|
| Age at diagnosis (y) | |
| Median (IQR) | 63 (57.7–67) |
| Y of diagnosis (biopsy) | |
| 2009 | 467 (8.7) |
| 2010 | 567 (10.6) |
| 2011 | 1162 (21.7) |
| 2012 | 1186 (22.2) |
| 2013 | 1060 (19.8) |
| 2014 | 897 (16.8) |
| Method of diagnosis | |
| TRUS | 4876 (91.3) |
| TURP | 93 (1.7) |
| Transperineal biopsy | 359 (6.7) |
| Other (TURBT, prostatectomy) | 9 (0.2) |
| Not stated | 2 (0.04) |
| Preoperative serum PSA level (ng/mL) | |
| Median (IQR) | 6 (4.5–8.3) |
| Clinical categories | |
| cT1 | 2,407 (45.1) |
| cT2 | 1,606 (30.1) |
| cT3/cT4 | 217 (4.0) |
| Not stated | 1,109 (20.7) |
| No. of biopsy cassettes | |
| Median (IQR) | 8 (6–8) |
| No. of positive biopsy cassettes | |
| Median (IQR) | 3 (2–5) |
| Positive biopsy cassettes (%) | |
| Median (IQR) | 42.8 (25–62.5) |
| < 25 | 1025 (19.2) |
| 25–62.5 | 2882 (53.9) |
| > 62.5 | 1273 (23.8) |
| Not stated | 159 (2.9) |
| NCCN Classification | |
| Low risk | 909 (17.0) |
| Intermediate risk | 3007 (56.3) |
| Metastatic risk | 1,134 (21.2) |
| Not stated | 289 (5.4) |
| Interval between biopsy & surgery (d) | |
| Median (IQR) | 59 (40–99) |
| < 40 | 1,327 (24.8) |
| 40–99 | 2,675 (50.1) |
| > 99 | 1,330 (24.9) |
| Not stated | 7 (0.1) |
| RP approach | |
| Robot-assisted laparoscopic | 2,821 (52.8) |
| Laparoscopic | 317 (5.9) |
| Open retropubic | 2,156 (40.4) |
| Not stated | 45 (0.8) |
| Hospital where biopsy/RP performed | |
| Private/private | 3,853 (72.2) |
| Private/public | 207 (3.8) |
| Public/private | 189 (3.5) |
| Public/public | 793 (14.8) |
| Not stated | 297 (5.5) |
| Hospital where biopsy/RP performed | |
| Metropolitan/metropolitan | 4,153 (77.8) |
| Metropolitan/regional | 13 (0.2) |
| Regional/metropolitan | 500 (9.3) |
| Regional/regional | 454 (8.5) |
| Not stated | 219 (4.1) |
| RP annual surgeon volume | |
| Median (IQR) | 33 (19–53) |
| Pathological categories | |
| pT2 | 2,901 (54.3) |
| pT3 | 2,078 (38.9) |
| pT4 | 8 (0.1) |
| Not stated | 352 (6.6) |
| Positive surgical margin | |
| Absent | 3,798 (71.1) |
| Present | 1,449 (27.1) |
| Not stated | 92 (1.7) |
| Extraprostatic extension | |
| No | 874 (16.3) |
| Yes | 924 (17.3) |
| Data collected prior to database | 3,296 (61.7) |
| Not stated | 245 (4.1) |
IQR, interquartile range; NCCN, National Comprehensive Cancer Network; PSA, prostate-specific antigen; RP, radical prostatectomy; TRUS, transrectal ultrasound; TURBT, transurethral resection of a bladder tumor; TURP, transurethral resection of the prostate.